Poseida Therapeutics (PSTX) IPO Opens Modestly Higher

Today's IPO for Poseida Therapeutics, Inc. (NASDAQ: PSTX) opened for trading at $17 after pricing 14,000,000 shares of its common stock at a price to the public of $16.00 per share.

In addition, Poseida has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the initial public offering price less underwriting discounts and commissions.

BofA Securities, Piper Sandler and William Blair are acting as joint book-running managers for the offering.

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Modification System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.

You May Also Be Interested In

• Rubrik IPO: 5 key things to know
• Serve Robotics (SERV) Opens At $4.75, IIPO At $4 (Earlier)
• Rubrik (RBRK) Files for 23M Share IPO at $28-$31/sh